What are our pharmacotherapeutic options for MERS-CoV?

Expert Review of Clinical Pharmacology

Volumn 7, Issue 3, 2014, Pages 235-238

  Al Tawfiq, Jaffar A ^a,b   Memish, Ziad A ^c,d  

^a DHAHRAN HEALTH CENTER   (Saudi Arabia)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MINISTRY OF HEALTH   (Saudi Arabia)

^d ALFAISAL UNIVERSITY   (Saudi Arabia)

Author keywords

Interferon; MERS CoV; Pegylated interferon; Ribavirin; Therapy

Indexed keywords

ADENOSINE DEAMINASE; ALPHA2A INTERFERON; ANTIVIRUS AGENT; BETA INTERFERON; CONSENSUS INTERFERON; CYCLOPHILIN INHIBITOR; CYCLOSPORIN A; DIPEPTIDYL PEPTIDASE IV; LOPINAVIR; MYCOPHENOLIC ACID; NELFINAVIR; PEGINTERFERON ALPHA2A; RIBAVIRIN; RITONAVIR; VIRUS RNA; IMMUNOLOGIC FACTOR;

ANTIVIRAL THERAPY; COMORBIDITY; CONVALESCENCE; CORONAVIRUS; CORONAVIRUS INFECTION; CRITICALLY ILL PATIENT; EDITORIAL; FATALITY; HUMAN; IMMUNE RESPONSE; IN VITRO STUDY; INTENSIVE CARE UNIT; LYMPHOCYTE PROLIFERATION; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS INFECTION; MORTALITY; OBSERVATIONAL STUDY; OPEN STUDY; PUBLICATION; SARS CORONAVIRUS; SYNDROME; SYSTEMATIC REVIEW (TOPIC); VIRUS ENTRY; VIRUS REPLICATION; ANIMAL; CORONAVIRUS INFECTIONS; DRUG COMBINATION; DRUG EFFECTS; IMMUNOLOGY; SEVERE ACUTE RESPIRATORY SYNDROME; VIROLOGY;

ANIMALS; ANTIVIRAL AGENTS; CORONAVIRUS INFECTIONS; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOLOGIC FACTORS; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; SARS VIRUS; SEVERE ACUTE RESPIRATORY SYNDROME;

EID: 84898922309     PISSN: 17512433     EISSN: 17512441     Source Type: Journal    
DOI: 10.1586/17512433.2014.890515     Document Type: Editorial

References (34)

1. WHO Middle East respiratory syndrome coronavirus (MERS-CoV) - update. Available from: www.who.int/csr/don/ 2014-01-09/en/index.html
2. Penttinen PM, Kaasik-Aaslav K, Friaux A, et al. Taking stock of the first 133 MERS coronavirus cases globally - is the epidemic changing? Euro Surveill 2013;18:39
3. ISARIC, International Severe Acute Respiratory & Emerging Infection Consortium. Clinical Decision Making Tool for Treatment of MERS-CoV v.1.0, 18 June 2013. Available from: www.hpa. org.uk/webc/HPAwebFile/HPAweb-C/ 1317139281416 [Last accessed 26 November 2013]
4. Momattin H, Mohammed K, Zumla A, et al. Therapeutic options for Middle East respiratory syndrome coronavirus (MERSCoV) - possible lessons from a systematic review of SARS-CoV therapy. Int J Infect Dis 2013;17(10):e792-8
5. Stockman LJ, Bellamy R, Garner P. SARS: systematic review of treatment effects. PLoS Med 2006;3(9):e343
6. Buchholz U, Muller MA, Nitsche A, et al. Contact investigation of a case of human novel coronavirus infection treated in a German hospital, October-November 2012. Euro Surveill 2013;18:20406.
7. Drosten C, Seilmaier M, Corman VM, et al. Clinical features and virological analysis of a case of Middle East respiratory syndrome coronavirus infection. Lancet Infect Dis 2013;13(9):745-51
8. Raj VS, Mou H. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature 2013;495(7440): 251-4
9. Raj VS, Smits SL, Provacia LB, et al. Adenosine deaminase acts as a natural antagonist for dipeptidyl peptidase 4 mediated entry of the middle east respiratory syndrome coronavirus. J Virol 2013. [Epub ahead of print]
10. Ohnuma K, Haagmans BL, Hatano R, et al. Inhibition of middle east respiratory syndrome coronavirus infection by Anti-CD26 monoclonal antibody. J Virol 2013;87(24):13892-9
11. Chan JF, Chan KH, Kao RY, et al. Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus. J Infect 2013;67(6):606-16
12. Hart BJ, Dyall J, Postnikova E, et al. Interferon-beta and mycophenolic acid are potent inhibitors of Middle East respiratory syndrome coronavirus in cell-based assays. J Gen Virol 2013. [Epub ahead of print]
13. Pfefferle S, Schöpf J, Kögl M, et al. The SARS-coronavirus-host interactome: identification of cyclophilins as target for pan-coronavirus inhibitors. PLoS Pathog 2011;7(10):e1002331
14. de Wilde AH, Raj VS, Oudshoorn D, et al. MERS-coronavirus replication induces severe in vitro cytopathology and is strongly inhibited by cyclosporin A or interferon-a treatment. J Gen Virol 2013;94(Pt 8): 1749-60
15. Smith EC, Blanc H, Vignuzzi M, Denison MR. Coronaviruses lacking exoribonuclease activity are susceptible to lethal mutagenesis: evidence for proofreading and potential therapeutics. PLoS Pathog 2013;9(8):e1003565
16. Poutanen SM, Low DE, Henry B, et al. Identification of severe acute respiratory Syndrome in Canada. N Eng J Med 2003;348:1995-2005
17. Tsang KW, Ho PL, Ooi GC, et al. A Cluster of Cases of Severe Acute Respiratory Syndrome in Hong Kong. N Eng J Med 2003;348:1977-85
18. Booth CM, Matukas LM, Tomlinson GA, et al. Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. JAMA 2003;290:334
19. Hsu LY, Lee CC, Green JA, et al. Severe acute respiratory syndrome (SARS) in Singapore: clinical features of index patient and initial contacts. Emerg Infect Dis 2003;9:713-17
20. Peiris JS, Chu CM, Cheng VC, et al. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet 2003;361: 1767-72
21. Zhao Z, Zhang F, Xu M, et al. Description and clinical treatment of an early outbreak of severe acute respiratory syndrome (SARS) in Guangzhou, PR China. J Med Microbiol 2003;52:715-20
22. Sung JJ, Wu A, Joynt GM, et al. Severe acute respiratory syndrome: report of treatment and outcome after a major outbreak. Thorax 2004;59:414-20
23. Chan KS, Lai ST, Chu CM, et al. Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study. Hong Kong Med J 2003;9:399-406
24. Chu CM, Cheng VC, Hung IF, et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax 2004;59:252-6
25. Loutfy MR, Blatt LM, Siminovitch KA, et al. Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study. JAMA 2003;290:3222-8
26. Lau SK, Lau CC, Chan KH, et al. Delayed induction of proinflammatory cytokines and suppression of innate antiviral response by the novel Middle East respiratory syndrome coronavirus: implications for pathogenesis and treatment. J Gen Virol 2013;94(Pt 12): 2679-90
27. Kindler E, Jónsdóttir HR, Muth D, et al. Efficient replication of the novel human betacoronavirus EMC on primary human epithelium highlights its zoonotic potential. MBio 2013;4(1):e00611-12
28. Zielecki F, Weber M, Eickmann M, et al. Human cell tropism and innate immune system interactions of human respiratory coronavirus EMC compared to those of severe acute respiratory syndrome coronavirus. J Virol 2013;87(9):5300-4
29. Hart BJ, Dyall J, Postnikova E, et al. Interferon-beta and mycophenolic acid are potent inhibitors of Middle East respiratory syndrome coronavirus in cell-based assays. J Gen Virol 2013. [Epub ahead of print]
30. Falzarano D, de Wit E, Martellaro C, et al. Inhibition of novel b coronavirus replication by a combination of interferon-a2b and ribavirin. Sci Rep 2013;3:1686
31. Falzarano D, de Wit E, Rasmussen AL, et al. Treatment with interferon-a2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques. Nat Med 2013;19(10):1313-17
32. de Wit E, Rasmussen AL, Falzaranoa D, et al. Middle East respiratory syndrome coronavirus (MERS-CoV) causes transient lower respiratory tract infection in rhesus macaques. Proc Natl Acad Sci USA 2013; 110(41):16598-603
33. Yao Y, Bao L, Deng W, et al. An animal model of MERS produced by infection of Rhesus Macaques with MERS coronavirus. J Infect Dis 2014;209(2):236-42
34. Al-Tawfiq JA, Momattin H, Dib J, Memish ZA. Ribavirin and interferon therapy in patients infected with the Middle East respiratory syndrome coronavirus: an observational study. Int J Infect Dis 2014. [Epub ahead of print]